(Sharecast News) - GlaxoSmithKline on Monday unveiled plans for a new £120m base for its consumer healthcare operations as it prepares to split into two listed firms.
Around 800 staff in the new firm will relocate to a yet-to-be-constructed building, including research facilities, in Weybridge, southwest of London, from the end of 2024. It will eventually house 1,400 workers.
Staff will first relocate from Glaxo's current corporate headquarters in Brentford, west London, to temporary facilities in Weybridge when the split takes place in mid-2022.
The business is a joint venture with Pfizer, which counts brands such as Sensodyne and Aquafresh toothpastes and Panadol painkillers among its product range.
Glaxo added that it would be selling the Brentford site, with the remaining pharmaceuticals and vaccines staff relocating in the same area, but not until at least the end of 2023.
Glaxosmithkline (GSK)Today 10:54
GSK raises profit outlook on strong vaccine, HIV drug sales
FY profit forecast raised to 8-10% *
